GlassScriptPhysician profile
Brian M Billings
NPI 1487647228
$4,679.13
in general payments reported to CMS, 2019-2025
36 companies · $1,467 in 2025
The $1,467 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $788 · 2020: $123 · 2021: $152 · 2022: $678 · 2023: $777 · 2024: $694 · 2025: $1,467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,798 · Education: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,797.67 |
| Education | $140.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,018.40 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $529.62 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $418.92 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $376.43 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $355.23 | 2021-2025 | |
| Novo Nordisk INC | $297.01 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $158.05 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.66 | 2019-2025 | Jardiance, Synjardy |
| Astellas Pharma US INC | $120.87 | 2023-2024 | Veozah |
| Jazz Pharmaceuticals INC. | $94.59 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $92.87 | 2022 | |
| Grt US Holding, INC. | $88.55 | 2022 | |
| Amarin Pharma, INC. | $79.15 | 2019-2022 | |
| Abbott Laboratories | $77.54 | 2022-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $71.81 | 2025 | Rexulti |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $63.04 | 2019-2024 | Yupelri |
| Glaxosmithkline, LLC. | $60.26 | 2019-2025 | Shingrix |
| Novartis Pharmaceuticals Corporation | $58.74 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $58.11 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $55.09 | 2022-2023 | Belsomra, Steglatro |
| Medtronic, INC. | $55.02 | 2025 | Intellis Adaptivestim |
| Phathom Pharmaceuticals, INC. | $52.51 | 2025 | Voquezna |
| Sumitomo Pharma America, INC. | $50.06 | 2024-2025 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $39.99 | 2019-2023 | Trintellix |
| Axsome Therapeutics, INC. | $37.81 | 2023-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $36.60 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $27.24 | 2019 | |
| Dexcom, INC. | $24.74 | 2021 | |
| Genzyme Corporation | $22.24 | 2025 | |
| Kyowa Kirin, INC. | $21.98 | 2025 | |
| Viatris Specialty LLC | $21.12 | 2025 | Yupelri |
| Xeris Pharmaceuticals, INC. | $19.64 | 2025 | Keveyis |
| Verona Pharma, INC. | $15.39 | 2025 | Ohtuvayre |
| Idorsia Pharmaceuticals US INC | $13.56 | 2025 | Quviviq |
| Allergan, INC. | $13.24 | 2020 | |
| Eisai INC. | $13.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Billings listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.